Mattias Klintemar

Mattias works as an Investment Director of Ostersjostiftelsen, or the Foundation for Eastern and European Studies, which is the largest owner of Palette Life Sciences. Mr. Klintemar has extensive experience from global management and board positions. Before he joined Ostersjostiftelsen he was CEO of a listed Swedish company, Morphic Technologies and he has also worked for the Nordic investment bank, ABG Sundal Collier and Arthur Andersen. He currently serves on the board of the listed companies Oatly, Moberg Pharma, OncoZenge and Biosergen. Mr. Klintemar holds a Bachelor’s degree in Accounting and Finance from Karlstad University.